Shares of Unichem Laboratories surged by 15% to hit a record high of ₹876.35 on Tuesday, demonstrating robust performance even in a generally weak market. This impressive rise reflects the company's healthy financial outlook.
Over the past two days, the stock has rallied by 20%, while in the last two weeks, it has zoomed by 42%. In contrast, the BSE Sensex experienced a 0.44% drop at 80,791 points during the same period.
Unichem's exceptional growth in 2024
Since the start of 2024, Unichem Labs' stock price has more than doubled, marking a staggering 115% increase. This is a significant leap compared to the benchmark index's 11.8% rise. For those looking into share market investment, this phenomenal growth underscores the potential of pharmaceutical companies in the stock market, particularly Unichem Labs, as it outperformed the broader market by a wide margin.
Strategic acquisition by Ipca Laboratories
In April 2023, Ipca Laboratories completed its acquisition of Unichem Labs for ₹1,830 crore, including non-core assets valued at ₹550 crore. This acquisition has strengthened Unichem's position in the United States, which remains a key market for the company.
Unichem's product portfolio has expanded, positioning the company as a significant player in the U.S. market. This strategic move has also proven beneficial for those interested in share market investment, as it further boosts the company’s value.
Synergies with Bayshore Pharmaceuticals
Unichem’s U.S. subsidiary, Unichem Pharmaceuticals (USA) Inc., entered into a significant agreement with Bayshore Pharmaceuticals LLC, a subsidiary of Ipca. The acquisition of Bayshore’s U.S. generics marketing and distribution business will enhance Unichem’s product offerings in the U.S. market.
Furthermore, the consolidation is expected to lower overhead costs related to marketing, logistics, and warehousing. This improved efficiency will likely lead to higher profits for Unichem, making it an attractive option for those involved in share market investment.
Expanding global footprint
With the support of Ipca, Unichem is set to grow its presence in international markets, including Brazil, Slovenia, and Myanmar. Additionally, business in the UK, South Africa, and Canada is expected to expand by 15-25%, solidifying Unichem's market position.
This growth potential adds another layer of attractiveness for individuals considering share market investment, as the company is poised for further expansion in key global markets.
Margin improvement and future outlook
Following Ipca’s acquisition, Unichem Labs has seen a notable improvement in its gross margin, increasing by 200 basis points (bps) to 61% in FY24 and reaching 64% in the first quarter of FY25. Analysts project a further increase to 66% by FY27.
Unichem's margin improvement is forecasted to rise from 6% in FY24 to 15% by FY27, driven by synergy benefits and operational efficiencies. For investors focused on share market investment, these financial improvements signal a bright future for the company.
Shift in industry focus and government support
The pharmaceutical industry, including companies like Unichem Labs, is transitioning from simply expanding capacity to adopting advanced technologies, green initiatives, and improving efficiency. Unichem Labs is well-positioned to benefit from these industry trends.
Furthermore, the Indian government’s focus on infrastructure development, reducing logistics costs, and policies aimed at enhancing the ease of doing business will increase the competitiveness of the sector. This adds to the positive long-term outlook for share market investment in pharmaceutical stocks like Unichem.
Unichem Laboratories' remarkable performance, strategic moves, and promising outlook make it a standout player in the share market investment space.
For android only